Company profile
Suzhou VencuBio Ltd.?was established in February 2021, guided by the unmet clinical needs, and is committed to the research and development of innovative drugs. The pipeline currently under research involves tumors, autoimmune diseases, respiratory diseases and other fields.
Venture Incubate Biotech is led by a team of scientists and works with professional biomedical investment institutions to create a unique innovative drug incubation platform in China. The company has gathered industry elites and formed an innovation team covering the whole process of innovative drug research and development, intellectual property protection, CMC, drug registration declaration, drug clinical research, business development and so on.
The company is located in Suzhou Industrial Park Biomedical Industrial Park, the company was founded at the beginning of the angel round investment of tens of millions of yuan, and has thousands of square meters of office space and R & D platform.
At present, the company has completed more than ten target studies of First-in-class drugs, five of the projects launched in the first phase have entered the candidate molecular screening optimization stage, and one has completed the in vitro and in vitro pharmacodynamic evaluation, and is expected to submit a Sino-US IND application next year.
Team
以科學(xué)家團(tuán)隊(duì)為主導(dǎo)，與專(zhuān)業(yè)的生物醫(yī)藥投資機(jī)構(gòu)共同打造國(guó)內(nèi)獨(dú)具特色的創(chuàng)新藥孵化平臺(tái)
Quality
提供高品質(zhì)創(chuàng)新藥自主研發(fā)服務(wù)，為人類(lèi)健康事業(yè)服務(wù)
World
腫瘤、自身免疫性疾病、呼吸系統(tǒng)疾病等多個(gè)領(lǐng)域國(guó)家化創(chuàng)新藥研發(fā)
用核心技術(shù)賦能研發(fā)，嚴(yán)把新藥研發(fā)質(zhì)量，加快新藥研發(fā)上市，引領(lǐng)全球創(chuàng)新，服務(wù)人類(lèi)健康
聯(lián)系我們